Rocket Lab: Iridium Could Explode EBITDA, But A Wildcard Decides If It's Worth It (NASDAQ:RKLB)
Rocket Lab (RKLB) has secured full funding for its Iridium (IRDM) acquisition without using its $3.6B bridge loan. Iridium's $500M annual EBITDA could turn RKLB's $80M loss into ~$420M EBITDA. Up to 72M new shares may be issued, with 17M contingent on stock price.
How this was made
The 30-second read
Why it matters
Deal transforms RKLB's financial profile, adding $500M EBITDA, but raises dilution concerns.
Market read
Significant M&A reshapes satellite launch market, potential price moves for both tickers.
What to watch
Regulatory approval risk and integration challenges.
Background
Rocket Lab announced acquisition of Iridium, financing details disclosed.
Ticker impact
Deal with Iridium fully funded, turning $80M loss into $420M EBITDA and issuing up to 72M new shares.
potential upside as EBITDA improves, offset by dilution pressure
EBITDA boost suggests profitability, but large share issuance may limit price gain.
Iridium's $500M annual EBITDA adds to Rocket Lab's earnings, making the acquisition financially attractive.
upward pressure as acquisition premium is priced in
Deal adds significant EBITDA, likely valued above current market.
Market effects
Boosts space launch sector earnings outlook.
US aerospace stocks may see lift.
Highlights consolidation trend in satellite communications.
Counterpoint
Dilution from 72M shares could outweigh EBITDA benefits, pressuring RKLB stock.
Key entities
- companyRocket Lab
US-listed aerospace launch provider (RKLB).
- companyIridium Communications
Satellite communications firm (IRDM).
